Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | IL6ST | P40189 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 7/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357656 | 1.00 | PPARA (0.50) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL3495345 | 0.97 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL28950479 | 0.96 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL28950477 | 0.96 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL3493546 | 0.96 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL23970492 | 0.96 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL16401217 | 0.90 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL28895898 | 0.90 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL15587060 | 0.90 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL16401218 | 0.90 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | PPARA 2173/4885IL6ST 4278/4885NAAA 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.